Dementia

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early detection of dementia across a variety of healthcare settings

Abstract Background The Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) is a structured interview based on informant responses that is used to assess for possible dementia. IQCODE has been used for retrospective or contemporaneous assessment of cognitive decline. There is considerable interest in tests that may identify those at future risk of developing […]

Share

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within a general practice (primary care) setting

Abstract Background The IQCODE (Informant Questionnaire for Cognitive Decline in the Elderly) is a commonly used questionnaire based tool that uses collateral information to assess for cognitive decline and dementia. Brief tools that can be used for dementia “screening” or “triage” may have particular utility in primary care / general practice healthcare settings but only […]

Share

Informant Questionnaire on Cognitive Decline in the Elderly for the detection of dementia within community dwelling populations

Abstract Background Various tools exist for initial assessment of possible dementia with no consensus on the optimal assessment method. Instruments that use collateral sources to assess change in cognitive function over time may have particular utility. The most commonly used informant dementia assessment is the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). A […]

Share

Mini‐Cog for the detection of dementia within a primary care setting

Abstract Background Alzheimer’s disease and other forms of dementia are becoming increasingly common with the aging of most populations. The majority of individuals with dementia will first present for care and assessment in primary care settings. There is a need for brief dementia screening instruments that can accurately detect dementia in primary care settings. The […]

Share

Mini‐Cog for the detection of dementia within a secondary care setting

Abstract Background The diagnosis of Alzheimer’s disease dementia and other dementias relies on clinical assessment. There is a high prevalence of cognitive disorders, including undiagnosed dementia in secondary care settings. Short cognitive tests can be helpful in identifying those who require further specialist diagnostic assessment; however, there is a lack of consensus around the optimal […]

Share

Montreal Cognitive Assessment for the detection of dementiamer’s disease and other dementias

Abstract Background Alzheimer’s disease and other forms of dementia are becoming increasingly common with the aging of most populations. The majority of individuals with dementia will first present for care and assessment in primary care settings. There is a need for brief dementia screening instruments that can accurately detect dementia in primary care settings. The […]

Share

Mini‐Cog for the detection of dementia within a community setting

Abstract Background Alzheimer’s disease and related forms of dementia are becoming increasingly prevalent with the aging of many populations. The diagnosis of Alzheimer’s disease relies on tests to evaluate cognition and discriminate between individuals with dementia and those without dementia. The Mini‐Cog is a brief, cognitive screening test that is frequently used to evaluate cognition […]

Share

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis

Abstract Background Vascular cognitive impairment (VCI) describes a broad spectrum of cognitive impairments caused by cerebrovascular disease, ranging from mild cognitive impairment to dementia. There are currently no pharmacological treatments recommended for improving either cognition or function in people with VCI. Three cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) are licenced for the treatment of dementia […]

Share

Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer’s disease dementia in participants diagnosed with any dementia subtype in a specialist care setting

Abstract Background Dementia is a syndrome that comprises many differing pathologies, including Alzheimer’s disease dementia (ADD), vascular dementia (VaD) and frontotemporal dementia (FTD). People may benefit from knowing the type of dementia they live with, as this could inform prognosis and may allow for tailored treatment. Beta‐amyloid (1‐42) (ABeta42) is a protein which decreases in […]

Share

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia

Abstract  Background Dementia is a progressive syndrome characterised by deterioration in memory, thinking and behaviour, and by impaired ability to perform daily activities. Two classes of drug ‐ cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and memantine ‐ are widely licensed for dementia due to Alzheimer’s disease, and rivastigmine is also licensed for Parkinson’s disease dementia. […]

Share
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share